All.Can

What All.Can does

All.Can is an international multi-stakeholder non-profit initiative focused on improving the efficiency of cancer care by centring the patient perspective. Established as All.Can International ASBL in Belgium (registration number 0746.638.692) with a Brussels secretariat, the initiative originated around 2016 and operates with 1-10 employees. It convenes patient organisations, policymakers, healthcare professionals, researchers and industry partners through working groups, national initiatives and annual Global Summits that have drawn up to 200 participants from 40 countries. All members contribute their time for free, and all publications are consensus-driven with full editorial control retained by members. Funding comes from twelve named pharmaceutical sponsors (Bristol Myers Squibb, Roche, MSD, Johnson & Johnson, BeOne Medicines, Exact Sciences, Daiichi-Sankyo, Amgen, Astellas, Becton Dickinson, Illumina, MNI) as well as EU joint-action grants including the iPAAC and TEHDAS programmes.

The organisation's core outputs are intellectual property rather than commercial products. The portfolio includes the Efficiency Metrics Study defining eight internationally applicable efficiency categories (developed with the University of Southampton and The Health Value Alliance), the Action Guide For Efficient Cancer Care (a digital implementation tool co-developed with Amsterdam UMC), the Efficiency Hub online repository cataloguing over 40 best-practice examples, and the Cancer Care Efficiency Heatmap visualisation. Supporting outputs include a Policy Blueprint on building efficiency in cancer care, a Policy Report on harnessing data for better cancer care, an international patient survey covering nearly 4,000 respondents across 10 countries, focus briefs on diagnosis and shared decision-making, and a 12-country Case Study Compendium on person-centred cancer care. Distribution is entirely free via the all-can.org website and through national initiatives that adapt frameworks locally in countries including Spain, UK, Belgium, Mexico, Norway, Poland and Sweden.

All.Can has no commercial pricing model. Revenue mechanics consist of unrestricted multi-sponsor pharmaceutical contributions and EU programme funding, channelled through membership contributions and the Belgian ASBL structure. The go-to-market is community-led: the organisation builds authority through peer-reviewed publications (e.g., Journal of Cancer Policy, Health Research Policy and Systems), earned media coverage (BMJ, Politico, MedicalXpress, Cancer World, Health Europa), events at the European Parliament and the European Health Forum Gastein, and strategic partnerships with the Union for International Cancer Control, the European Alliance for Value in Health, the OECD and EFPIA. All.Can does not operate as a technology vendor and has no APIs, apps or proprietary AI capabilities.

Name

All.Can

Legal name

All.Can International ASBL

Website

https://all-can.org

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

All.Can is an international non-profit coalition that produces evidence-based frameworks, policy reports and digital tools to improve the efficiency and person-centredness of cancer care for policymakers, clinicians and patient organisations across 40+ countries.

Ownership category

akta.pro rank

Product category

Healthcare Policy Research

NAICS

Research and Development in the Social Sciences and Humanities (54172), Social Assistance (624)

SIC

Services-Health Services (8000)

akta.pro primary industry

Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)

akta.pro secondary industries

Health Systems Performance & Quality Measurement (Public Sector) (HLAJANAK), Quality Measurement, Reporting & Benchmarking (HEDIS/Stars/CQM) (HLACAHAC)

Keywords

• Cancer care efficiency
• Health policy research
• Patient-centred care
• Cancer policy advocacy
• Multi-stakeholder coalition

Headquarters

HQ city

North Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Pharmaceutical Industry Funding: All.Can receives financial support from pharmaceutical companies including Bristol Myers Squibb, Roche, MSD, Johnson & Johnson, BeOne Medicines, Exact Sciences, and Daiichi-Sankyo. Members contribute their time for free to the initiative.
2. EU Funding: As a collaborating partner in iPAAC (Innovative Partnership for Action Against Cancer), All.Can participates in EU Third Health Programme (2014-2020) funded joint actions.
3. Membership Contributions: All.Can operates as a not-for-profit organisation (ASBL) registered in Belgium. Revenue comes from membership contributions and affiliations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

All.Can produces evidence-based policy research, frameworks, and digital tools designed to improve the efficiency of cancer care delivery. Its core outputs include the Action Guide For Efficient Cancer Care (a digital implementation tool), the Efficiency Hub (an online repository of best-practice examples), the Cancer Care Efficiency Heatmap (a visual analytics tool), the Efficiency Metrics Study, and policy blueprints and reports. All products are made freely available to policymakers, healthcare professionals, patient organisations, and researchers through the All.Can website and national chapter initiatives.

Product overview

All.Can is an international multi-stakeholder not-for-profit initiative that improves efficiency of cancer care through policy research, frameworks, and knowledge-sharing platforms. The core offering consists of the Action Guide For Efficient Cancer Care (a digital implementation tool), the Efficiency Hub (an online repository of best practices), and the Cancer Care Efficiency Heatmap (a visualization tool). Supporting publications include the Efficiency Metrics Study, Policy Blueprint, and Policy Report on data. The International Patient Survey and related Focus Briefs provide patient-derived insights, while the Case Study Compendium documents twelve international examples of person-centred care. These products work together as a comprehensive reform and accountability architecture: defining what good cancer care looks like and measuring how close systems are to achieving it.

Differentiator

Problem solved

Functional benefit

Brands

• Efficiency Hub: An online platform gathering examples of best practice in cancer care from around the world to create a learning community.
• Cancer Care Efficiency Map

Products and services

• Action Guide For Efficient Cancer Care A digital implementation tool supporting the operationalization of cancer care efficiency metrics across health systems; assesses performance across three dimensions — timeliness of care, coordination of care, and patient-centredness. Developed with Amsterdam UMC and intended for health system decision-makers, clinicians, and policy implementers.
• Efficiency Hub A web-based repository gathering 40+ examples of best practice in cancer care from around the world to help organisations find and implement solutions to common efficiency challenges; intended for healthcare providers, policymakers, and patient organisations.
• Cancer Care Efficiency Heatmap A visual analytics display showing how the efficiency measures identified in the All.Can Policy Blueprint are implemented across different regions and health systems; used by policymakers and analysts for comparative policy review.
• All.Can International Patient Survey An international survey gathering insights from 3,981 cancer patients and caregivers across 10 countries to identify inefficiencies in cancer care from the patient perspective; intended for policymakers, healthcare providers, and patient organisations.
• All.Can Efficiency Metrics Study A policy research study proposing 8 internationally applicable, real-world measures (metric categories) for assessing efficiency in cancer care across timeliness, coordination, and patient-centredness; produced in partnership with The Health Value Alliance and University of Southampton.
• Policy Blueprint: Building Efficiency in Cancer Care Flagship policy publication highlighting key areas of inefficiency in cancer care and offering a common framework to support collaborative policy action; intended for policymakers and health system decision-makers.
• Policy Report: Harnessing Data for Better Cancer Care A policy report assessing the essential role of data in cancer care and offering a forward-looking view for policymakers, care providers, and decision-makers on improving cancer outcomes.
• Focus Briefs A series of four publication briefs offering deeper analysis of key opportunities for improving cancer care efficiency based on patient survey responses, covering diagnosis, information-sharing and shared decision-making, multidisciplinary care, and financial impact.
• Case Study Compendium on Person-Centred Cancer Care A compendium documenting twelve international examples of person-centred cancer care in practice from 12 countries, accompanying the global report on person-centred cancer care pathways.

Quantifiable outcome

• Cancer diagnoses projected to rise by nearly 77% by 2050, highlighting urgent need for efficiency improvements
• +2 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core.

• Organisation for Economic Co-operation and Development (OECD)coreStrategic or Co-development Partner · 17 March 2024All.Can contributed valuable insights to OECD report 'Beating Cancer Inequalities in the EU – Spotlight on Cancer Prevention and Early Detection'. Provided perspectives on efficiency throughout cancer care continuum.
• European Federation of Pharmaceutical Industries and Associations (EFPIA)coreStrategic or Co-development Partner · 3 November 2023All.Can endorsed and contributed to EFPIA report 'Rethink of European Cancer Services' addressing future demand for cancer care.
• The Health Value AlliancecoreStrategic or Co-development Partner · 17 June 2022Produced the Efficiency Metrics study in partnership with the University of Southampton. Research combined findings from 83 academic articles, 43 grey literature publications, 15 cancer registry websites.
• University of SouthamptoncoreStrategic or Co-development Partner · 17 June 2022Partnered with The Health Value Alliance to produce the Efficiency Metrics study. Academic research partner contributing to cancer care efficiency research.
• Union for International Cancer Control (UICC)coreStrategic or Co-development Partner · 18 May 2021All.Can joined UICC as an associate member. UICC has over 1200 member organisations in 172 countries and collaborates with more than 50 strategic partners. All.Can will advance the vision that efficient cancer care delivers the best possible health outcomes.
• European Alliance for Value in Health (EAVH)coreStrategic or Co-development Partner · 17 May 2021All.Can joined EAVH as an affiliate partner in 2021. EAVH represents patients, scientific societies, healthcare managers, hospitals, payers and industry working towards value-based, sustainable, people-centred health systems.
• Joint Action Towards the European Health Data Space (TEHDAS)coreStrategic or Co-development Partner · 8 April 2021All.Can selected to participate in TEHDAS stakeholder forum and Work Package 4 forum dedicated to outreach, engagement and sustainability. TEHDAS develops European principles for secondary use of health data.
• Innovative Partnership for Action Against Cancer (iPAAC)coreStrategic or Co-development PartnerAll.Can is a collaborating partner in iPAAC, a joint action of the European Commission. Working on Work Package 8 addressing challenges of cancer care. Partnering with Azienda USL – IRCCS di Reggio Emilia and Organisation of European Cancer Institutes (OECI) on surveys of cancer centres across Europe.
• Quality HealthcoreStrategic or Co-development PartnerDesign and conduct of the All.Can patient survey led by Quality Health, a specialist health and social care survey organisation. Provided survey design, methodology and analysis expertise.
• Amsterdam UMC (University of Amsterdam)coreStrategic or Co-development PartnerResearch team from Health Care Systems and Services research unit in Department of Public and Occupational Health at Amsterdam UMC developed the Action Guide For Efficient Cancer Care. Team included Dr Ana Sofia Carvalho, Dr Damir Ivanković, Dr Erica Barbazza, Dr Óscar Brito Fernandes, Professor Niek Klazinga, and Dr Dionne Kringos.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Organisation of European Cancer Institutes (OECI): OECI is a European network of cancer centres working on quality, accreditation, and benchmarking of cancer care. All.Can partnered with OECI on iPAAC Work Package 8 surveys of cancer centres, making it a directly comparable peer in cancer care quality measurement.
• Union for International Cancer Control (UICC): UICC is a global multi-stakeholder cancer organization with 1,200+ members across 172 countries. All.Can is an associate member of UICC, and the two operate overlapping cancer advocacy and policy missions, making UICC the closest direct comparator.
• European Cancer Organisation (ECO): ECO is a not-for-profit federation of European cancer societies, patient groups, and industry focused on improving cancer care policy and outcomes. Like All.Can, it convenes multi-stakeholder coalitions and produces policy frameworks for cancer care across Europe.
• European Alliance for Value in Health (EAVH): EAVH is a multi-stakeholder alliance representing patients, scientific societies, healthcare managers, hospitals, payers, and industry to advance value-based, people-centred health systems. All.Can joined EAVH as an affiliate partner in 2021, making it a closely aligned peer in value-based cancer care policy.

Broad incumbents

• OECD Health Division: OECD produces influential health system performance reports and policy analysis used by member governments globally. All.Can contributed to the OECD report 'Beating Cancer Inequalities in the EU', placing it adjacent to — and partially overlapping with — OECD's broader health policy work.
• World Health Organization - Cancer Control Programme: WHO's cancer control programme sets global norms and guidelines for cancer prevention, treatment, and palliative care. It is the ultimate global incumbent in cancer policy that All.Can interacts with and complements through its multi-stakeholder coalition model.
• National Comprehensive Cancer Network (NCCN): NCCN is a US-based alliance of leading cancer centres that publishes widely adopted clinical practice guidelines and oncology outcome measures. It overlaps with All.Can's work on cancer care quality metrics but operates more as a clinical guidance body than a policy coalition.
• Cancer Research UK: Cancer Research UK is one of the world's largest cancer research charities, funding research, influencing policy, and engaging patients. It is comparable to All.Can as a large-scale cancer-focused non-profit with policy influence, though its scope is much broader including basic research.

Emerging players

• ICHOM (International Consortium for Health Outcomes Measurement): ICHOM is a non-profit that develops standardized outcome sets and value-based care frameworks across disease areas, including cancer. It overlaps with All.Can's mission of standardizing efficiency metrics and patient-centred outcomes measurement across health systems.

Others

• European Federation of Pharmaceutical Industries and Associations (EFPIA): EFPIA is the European pharmaceutical industry's trade association, with which All.Can partnered on cancer care policy reports. While not a direct peer, EFPIA is a key funder counterpart and ecosystem participant in All.Can's cancer efficiency policy work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/allcangroup
• YouTubeyoutube.com/channel/UCBGVoS4g7nvM2fmBpX0qoyg
• Facebookfacebook.com/AllCanGroup
• LinkedInlinkedin.com/company/all-can-canada

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about All.Can